Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 (GLOBE ...
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan ...
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Hi! I am a psychiatric mental health nurse practitioner with more than 20 years' experience. I work with young children, adolescents, adults and seniors. My goal is to help you or your family member ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results